Loading...
25 sotrovimab COVID-19 controlled studies, 2 RCTs
30% improvement
for early treatment, RR
0.70
[0.57-0.86]
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
COMET-ICE
Gupta (DB RCT)
80%
0.20 [0.01-4.16]
death
0/528
2/529
Improvement, RR [CI]
Treatment
Control
COMET-ICE
Gupta (DB RCT)
89%
0.11 [0.01-2.06]
ventilation
0/528
4/529
COMET-ICE
Gupta (DB RCT)
75%
0.25 [0.11-0.57]
progression
7/528
28/529
COMET-ICE
Gupta (DB RCT)
79%
0.21 [0.09-0.50]
death/hosp.
6/528
30/529
Ong
61%
0.39 [0.05-2.90]
death
1/19
10/75
Ong
56%
0.44 [0.11-1.73]
ICU
2/19
18/75
Ong
59%
0.41 [0.17-0.99]
progression
19 (n)
75 (n)
Aggarwal (PSM)
89%
0.11 [0.00-0.79]
death
0/522
15/1,563
Aggarwal (PSM)
62%
0.38 [0.20-0.67]
hosp.
11/522
89/1,563
Aggarwal (PSM)
-11%
1.11 [0.78-1.53]
progression
44/522
119/1,563
Zaqout
-165%
2.65 [0.60-11.3]
progression
4/345
3/583
Aggarwal
38%
0.62 [0.07-2.77]
death
1/1,542
7/3,663
Aggarwal
18%
0.82 [0.56-1.18]
hosp.
39/1,542
116/3,663
Aggarwal
-3%
1.03 [0.80-1.29]
progression
93/1,542
224/3,663
Piccicacco
66%
0.34 [0.01-8.13]
death
0/88
1/90
Piccicacco
35%
0.65 [0.26-1.60]
hosp.
7/88
11/90
Piccicacco
66%
0.34 [0.14-0.76]
hosp./ER
7/88
21/90
Piccicacco
90%
0.10 [0.01-0.78]
progression
1/88
10/90
Kneidinger
-20%
1.20 [0.64-2.27]
severe case
21/125
13/93
Suzuki
-8%
1.08 [0.69-1.70]
progression
672 (n)
1,257 (n)
Brown
-258%
3.58 [0.73-17.5]
hosp.
6/186
2/222
Zheng
50%
0.50 [0.31-0.81]
death/hosp.
34/3,331
61/2,689
OT1
Zheng
46%
0.54 [0.33-0.88]
death/hosp.
32/3,331
55/2,689
OT1
Zheng (PSW)
4%
0.96 [0.52-1.79]
death/hosp.
2,847 (n)
4,836 (n)
OT1
Zheng (PSW)
-14%
1.14 [0.58-2.22]
death/hosp.
19/2,847
33/4,836
OT1
Evans
27%
0.73 [0.55-0.98]
death/hosp.
1,079 (n)
4,973 (n)
Goodwin
75%
0.25 [0.01-5.17]
death
0/169
2/336
Goodwin
60%
0.40 [0.09-1.79]
hosp.
2/169
10/336
Goodwin
-21%
1.21 [0.59-2.51]
hosp.
11/169
18/336
Kip
30%
0.70 [0.43-1.12]
death/hosp.
22/500
63/999
Tazare
16%
0.84 [0.75-0.93]
death/hosp.
Miyashita
60%
0.40 [0.08-2.06]
ventilation
2/844
5/844
Miyashita
33%
0.67 [0.11-3.98]
ventilation
2/642
3/642
Miyashita
80%
0.20 [0.01-4.14]
ventilation
0/202
2/202
Miyashita
55%
0.45 [0.30-0.66]
oxygen
34/844
76/844
Miyashita
54%
0.46 [0.30-0.73]
oxygen
26/642
56/642
Miyashita
60%
0.40 [0.18-0.89]
oxygen
8/202
20/202
Drysdale (PSW)
29%
0.71 [0.16-3.20]
death
599 (n)
5,191 (n)
Drysdale (PSW)
50%
0.50 [0.24-1.06]
death/hosp.
599 (n)
5,191 (n)
Drysdale (PSW)
57%
0.43 [0.18-1.00]
hosp.
599 (n)
5,191 (n)
De Vito
81%
0.19 [0.07-0.47]
death
18/341
63/348
De Vito
92%
0.08 [0.03-0.17]
oxygen
17/341
144/348
Behzad
74%
0.26 [0.11-0.59]
death/ICU
569 (n)
611 (n)
Bell (PSW)
24%
0.76 [0.66-0.88]
death/hosp.
population-based cohort
Bell (PSW)
21%
0.79 [0.68-0.90]
hosp.
population-based cohort
Farmer (PSM)
-20%
1.20 [0.91-1.58]
death/hosp.
1,603 (n)
6,299 (n)
Bell (PSM)
50%
0.50 [0.19-1.33]
death
5/854
20/1,708
Bell (PSM)
12%
0.88 [0.53-1.45]
death/hosp.
21/854
48/1,708
Bell (PSM)
74%
0.26 [0.09-0.73]
ICU
4/854
31/1,708
Bell (PSM)
59%
0.41 [0.28-0.60]
oxygen
30/854
148/1,708
Bell (PSM)
-20%
1.20 [0.67-2.14]
hosp.
18/854
30/1,708
Maria (PSW)
72%
0.28 [0.04-1.42]
death
39 (n)
42 (n)
Maria (PSW)
77%
0.23 [0.05-0.83]
progression
39 (n)
42 (n)
TICO
Self (DB RCT)
-2%
1.02 [0.48-2.17]
death
14/182
13/178
TICO
Self (DB RCT)
11%
0.89 [0.73-1.10]
no recov.
22/182
27/178
TICO
Self (DB RCT)
7%
0.93 [0.63-1.35]
no recov.
181 (n)
178 (n)
Woo (PSM)
-140%
2.40 [0.78-7.41]
death
4/60
10/360
Woo (PSM)
-50%
1.50 [0.98-2.29]
death
36/87
24/87
Sotrovimab COVID-19 outcomes
c19 early .org
December 2024
1 OT: comparison with other treatment
Favors sotrovimab
Favors control
Figure S2. Comparison of results for RCTs versus observational studies.
For COVID-19 treatments, there is no significant difference between the results of RCTs and observational studies. Observational studies do not systematically over or underestimate efficacy. For high-cost treatments, there is a non-significant trend towards RCTs showing greater efficacy.
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers.
Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit